Zobrazeno 1 - 10
of 155
pro vyhledávání: '"JOHN WEN-CHENG CHANG"'
Autor:
Hung-Chih Hsu, Wen-Hung Chung, Yung-Chang Lin, Tsai-Sheng Yang, John Wen-Cheng Chang, Chia-Hsun Hsieh, Shuen-Iu Hung, Chun-Wei Lu, Jen-Shi Chen, Wen-Chi Chou, Chuang-Wei Wang
Publikováno v:
Allergology International, Vol 73, Iss 4, Pp 580-586 (2024)
Background: Oxaliplatin is commonly used to treat gastrointestinal malignancies. However, its applications are limited due to potential adverse drug reactions (ADRs), particularly severe anaphylactic shock. There is no method to predict or prevent AD
Externí odkaz:
https://doaj.org/article/4b81483c25e349828a372588dbf291c6
Autor:
Jin-Yuan Shih, Yung-Hung Luo, Gee-Chen Chang, John Wen-Cheng Chang, Chin-Chou Wang, Tsung-Ying Yang, Wei-Tse Fang, Wen-Yi Shau
Publikováno v:
Journal of the Formosan Medical Association, Vol 123, Iss 8, Pp 875-881 (2024)
Background: Lorlatinib is a brain-penetrant, third-generation anaplastic lymphoma kinase (ALK) inhibitor indicated for ALK-positive metastatic non-small cell lung cancer (NSCLC). In a global phase II study, patients who experience disease progression
Externí odkaz:
https://doaj.org/article/a761d4469e6046f0991578a068010259
Autor:
Hung-Hui Wei, Ying-Chieh Lai, Gigin Lin, Cheng-Wei Lin, Ya-Chu Chang, John Wen-Cheng Chang, Miaw-Jene Liou, I-Wen Chen
Publikováno v:
Diabetology & Metabolic Syndrome, Vol 16, Iss 1, Pp 1-10 (2024)
Abstract Background Immune checkpoint inhibitors (ICI) are promising treatment options for various cancers. However, their use is associated with immune-related adverse events (irAEs), including ICI-induced diabetes mellitus (ICI-DM). This study aime
Externí odkaz:
https://doaj.org/article/0c74cd8ef065457ab3824351707e78d0
Autor:
Chiao-En Wu, Yi-Hua Liao, Cheng-Lin Wu, Ruoh-Fang Yen, Chia-Chi Lin, Muh-Hwa Yang, Chueh-Chuan Yen, Wu-Chou Su, Chia-Jui Yen, Yi-Fang Chang, Ming-Fang Wu, Youngsen Yang, Chen-Yuan Lin, Wen-Chi Yang, Hui-Ching Wang, Cheng-Yuan Li, Yin-Yu Ho, Yao-Yu Chang, Chieh-Shan Wu, Hsiu-Cheng Hsu, Kuang-Hua Chen, Yenlin Huang, Chih-Jung Chen, Pei-Ju Chuang, Yung-Chi Lai, Yu-Yi Huang, Neng-Chuan Tseng, Yi-Ting Huang, Chia-Yu Chu, John Wen-Cheng Chang
Publikováno v:
Journal of the Formosan Medical Association, Vol 123, Iss 1, Pp 7-15 (2024)
Melanoma is rare in Taiwan. Asian melanoma is distinct from Western melanoma because acral and mucosal melanoma accounts for the majority of melanoma cases, leading to distinct tumor behaviors and genetic profiling. With consideration of the clinical
Externí odkaz:
https://doaj.org/article/04854f0faec04d159246a6f4a85d5aa9
Autor:
Chen‐Te Wu, Ping‐Chih Hsu, John Wen‐Cheng Chang, Ching‐Fu Chang, Chen‐Yang Huang, Cheng‐Ta Yang, Chih‐Hsi Scott Kuo, Yueh‐Fu Fang, Chiao‐En Wu
Publikováno v:
Thoracic Cancer, Vol 14, Iss 25, Pp 2548-2557 (2023)
Abstract Background This study aimed to comprehensively evaluate the efficacy and toxicity of afatinib in patients with sarcopenia, an important prognostic factor for treatment efficacy and toxicity in patients with cancer. Methods The clinical featu
Externí odkaz:
https://doaj.org/article/fc07701970254cbbb9979c7ef0d94271
Autor:
Shuen-Iu Hung, Mu-Tzu Chu, Ming-Mo Hou, Yun-Shien Lee, Chan-Keng Yang, Sung-Yu Chu, Feng-Yuan Liu, Hung-Chih Hsu, Shih-Cheng Pao, Yu-Chuan Teng, Chun-Bing Chen, Angel Chao, Wen-Hung Chung, John Wen-Cheng Chang, Chyong-Huey Lai
Publikováno v:
Biomedicine & Pharmacotherapy, Vol 169, Iss , Pp 115928- (2023)
Neoantigen-reactive cytotoxic T lymphocytes play a vital role in precise cancer cell elimination. In this study, we demonstrate the effectiveness of personalized neoantigen-based T cell therapy in inducing tumor regression in two patients suffering f
Externí odkaz:
https://doaj.org/article/bad26cd210654a5bb7eb4d83a3412e3b
Autor:
John Wen‐Cheng Chang, Ching‐Fu Chang, Chen‐Yang Huang, Cheng‐Ta Yang, Chih‐Hsi Scott Kuo, Yueh‐Fu Fang, Ping‐Chih Hsu, Chiao‐En Wu
Publikováno v:
Thoracic Cancer, Vol 14, Iss 4, Pp 348-356 (2023)
Abstract Background Epidermal growth factor receptor‐tyrosine kinase inhibitors (EGFR‐TKIs) are standard treatments for advanced non–small cell lung cancer (NSCLC) patients harboring the EGFR mutation. Patients experiencing intolerable adverse
Externí odkaz:
https://doaj.org/article/0d49cc0b61db45fda87814ded7764b7b
Autor:
John Wen‐Cheng Chang, Chen‐Yang Huang, Yueh‐Fu Fang, Ching‐Fu Chang, Cheng‐Ta Yang, Chih‐Hsi Scott Kuo, Ping‐Chih Hsu, Chiao‐En Wu
Publikováno v:
Thoracic Cancer, Vol 14, Iss 1, Pp 12-23 (2023)
Abstract Background Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR‐TKIs) are the standard treatment for patients with non‐small cell lung cancer (NSCLC) harboring EGFR mutations. This study aimed to evaluate the efficacy of EGF
Externí odkaz:
https://doaj.org/article/34e2b99597da430da22ea8c1cd7a1a29
Autor:
John Wen‐Cheng Chang, Chen‐Yang Huang, Yueh‐Fu Fang, Ching‐Fu Chang, Cheng‐Ta Yang, Chih‐Hsi Scott Kuo, Ping‐Chih Hsu, Chiao‐En Wu
Publikováno v:
Thoracic Cancer, Vol 13, Iss 13, Pp 1888-1897 (2022)
Abstract Background This study aimed to evaluate possible treatment strategies for patients with de novo T790M mutation‐positive (T790M+) non‐small‐cell lung cancer (NSCLC). Methods Patients diagnosed with de novo T790M+ NSCLC and treated with
Externí odkaz:
https://doaj.org/article/3fb18d1476c941f1b93a00a6782c7da0
Autor:
John Wen‐Cheng Chang, Chien‐Jung Huang, Wen‐Kuan Huang, Yu‐Chao Wang, Jia‐Juan Hsieh, Yao‐Yu Chang, Yen‐Lin Huang, Chia‐Ling Wu, Yeh‐Han Wang, Shu‐Jen Chen, Kien Thiam Tan, Chiao‐Ping Chen, Chiao‐En Wu
Publikováno v:
Clinical & Translational Immunology, Vol 12, Iss 8, Pp n/a-n/a (2023)
Abstract Objective Genomic biomarkers predicting immune checkpoint inhibitor (ICI) treatment outcomes for Asian metastatic melanoma have been rarely reported. This study presents data on next‐generation sequencing (NGS) and tumour microenvironment
Externí odkaz:
https://doaj.org/article/9d3e16d3182b40b6b8ab13363b85fb2d